Search Results
Mar 02, 2026, 07:00 ET Defense Metals Provides Update on Wicheeda Project Development
economics of the Wicheeda Project as presented in the PFS, which was based on 2030 prices of US$132.70/kg. The current international price is double the price of NdPr at the time MP Materials announced a floor price of $110/kg on July 10, 2025.PFS highlights include:Pre-tax
More news about: Defense Metals Corp.
Mar 02, 2026, 06:30 ET U.S. GoldMining Announces Positive Preliminary Economic Assessment for Whistler Gold-Copper Project, Alaska
immediate next steps, which may include further advancing the Project towards a possible pre-feasibility study ("PFS"). Additional work is required for the Company to determine whether to proceed to a PFS. Near term work programs could include commencement of waste rock geochemical characterization and storage
More news about: U.S. GoldMining Inc.
Mar 01, 2026, 19:00 ET Jaypirca® (Pirtobrutinib) Approved in China for the Treatment of Relapsed or Refractory Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma
is progression-free survival (PFS) per 2018 International Workshop on Chronic Lymphocytic Leukemia (iwCLL) criteria, as assessed by blinded independent review committee (IRC). Secondary endpoints include PFS, as assessed by investigator;
More news about: Innovent Biologics
Feb 25, 2026, 16:25 ET RAMACO RESOURCES REPORTS FOURTH QUARTER AND FULL-YEAR 2025 RESULTS
OUTLOOKRare Earths and Critical Minerals:The Company continues to progress to development of a Pre-Feasibility Study ("PFS"). It is announcing today that it has developed a fundamental alternative flowsheet design for the processing of its rare earth elements and critical
More news about: Ramaco Resources, Inc.
Feb 24, 2026, 07:15 ET ADC Therapeutics to Participate in March Investor Conferences
timing, publication and outcome of the full LOTIS-7 trial, compendia inclusion and regulatory strategy and the commercial opportunity; the timing of the PFS events and topline data release for LOTIS-5 and the results of the trial, the timing for the sBLA submission and full FDA approval; the Company's ability
More news about: ADC Therapeutics SA
Feb 24, 2026, 07:00 ET Defense Metals Showcases Rare Earth Leadership in European Trade Mission Led by Canadian Government
as detailed in the Company's 2025 Pre Feasibility Study ("PFS") (refer to Company News Release April 7th, 2025) prepared in accordance with National Instrument 43-101 Standards of Disclosure for Mineral Projects ("NI 43-101"). The PFS, showed the economic potential of the deposit, supporting
More news about: Defense Metals Corp.
Feb 23, 2026, 07:15 ET ADC Therapeutics Announces Amended HealthCare Royalty Financing Agreement
timing, publication and outcome of the full LOTIS-7 trial, compendia inclusion and regulatory strategy and the commercial opportunity; the timing of the PFS events and topline data release for LOTIS-5 and the results of the trial, the timing for the sBLA submission and full FDA approval; the Company's ability
More news about: ADC Therapeutics SA
Feb 23, 2026, 07:00 ET Defense Metals' Wicheeda Project Selected as One of only Three New Promising Projects by the British Columbia Critical Minerals Office for their Advanced Project Initiative
as detailed in the Company's 2025 Pre Feasibility Study ("PFS") (refer to Company News Release April 7th, 2025) prepared in accordance with National Instrument 43-101 Standards of Disclosure for Mineral Projects ("NI 43-101"). The PFS, showed the economic potential of the deposit, supporting
More news about: Defense Metals Corp.
Feb 22, 2026, 19:10 ET CStone Announces MHRA Approval in UK for Sugemalimab in Stage III NSCLC
double-blind Phase III trial. Results demonstrated that sugemalimab provided statistically significant improvement in progression-free survival (PFS) and a clinically meaningful prolongation of overall survival (OS) in patients with stage III NSCLC.To date, CStone has established four
More news about: CStone Pharmaceuticals
Feb 20, 2026, 02:00 ET U.S. Food and Drug Administration (FDA) Approves Combination Treatment of VENCLEXTA® (venetoclax) and Acalabrutinib for Previously Untreated Patients With Chronic Lymphocytic Leukemia (CLL)
the risk of disease progression or death by 35% versus chemoimmunotherapy (HR 0.65; 95% CI: 0.49-0.87; p=0.0038). Median progression-free survival (PFS) was not reached versus 47.6 months for chemoimmunotherapy. The safety profile of the VENCLEXTA and acalabrutinib combination regimen is consistent with
More news about: AbbVie
Feb 19, 2026, 17:00 ET RYBREVANT FASPRO™ (amivantamab and hyaluronidase-lpuj) plus immunotherapy shows strong clinical benefit with 56 percent overall response rate in first-line recurrent or metastatic head and neck cancer
Phase 3 studies, including MARIPOSA, have demonstrated the clinical benefit of RYBREVANT® in improving progression-free survival (PFS) and overall survival (OS) in advanced EGFR-mutated non-small cell lung cancer (NSCLC).RYBREVANT® is approved in the U.S., Europe
More news about: Johnson & Johnson
Feb 18, 2026, 07:30 ET RYBREVANT FASPRO™ (amivantamab and hyaluronidase-lpuj) receives U.S. FDA Breakthrough Therapy Designation for patients with advanced head and neck cancer
Phase 3 studies, including MARIPOSA, have demonstrated the clinical benefit of RYBREVANT® in improving progression-free survival (PFS) and overall survival (OS) in advanced EGFR-mutated non-small cell lung cancer (NSCLC).RYBREVANT® is approved in the U.S., Europe
More news about: Johnson & Johnson
Feb 17, 2026, 08:00 ET FDA approves RYBREVANT FASPRO™ (amivantamab and hyaluronidase-lpuj) as the only EGFR-targeted therapy that can be administered once a month
primary endpoint of the study is PFS (using RECIST v1.1 guidelines) as assessed by Blinded Independent Central Review (BICR). Secondary endpoints include overall survival (OS), ORR, duration of response (DoR), progression-free survival after first subsequent therapy (PFS2) and intracranial PFS.8Resistance
More news about: Johnson & Johnson
Feb 17, 2026, 07:00 ET Thesis Gold Rebrands to Thesis Gold & Silver
Project"). The PFS is based on a Mineral Resource of 4.56 million gold-equivalent ("AuEq") ounces in the Measured and Indicated category ("M&I") at an average grade of 1.21 grams per tonne ("g/t"), including 97.89 million ounces of silver at 25.9 g/t. The PFS outlines average
More news about: Thesis Gold Inc.
Feb 17, 2026, 07:00 ET Defense Metals Announces Pilot-Scale Flotation Test Program for Wicheeda Rare Earth Project
as detailed in the Company's 2025 Pre Feasibility Study ("PFS") (refer to Company News Release April 7th, 2025) prepared in accordance with National Instrument 43-101 Standards of Disclosure for Mineral Projects ("NI 43-101"). The PFS, showed the economic potential of the deposit, supporting
More news about: Defense Metals Corp.
Feb 17, 2026, 06:00 ET IDEAYA Biosciences Reports Fourth Quarter and Full Year 2025 Financial Results and Provides a Business Update
topline PFS results," said Yujiro S. Hata, President and Chief Executive Officer, IDEAYA Biosciences.Selected Recent Developments and Upcoming MilestonesDarovasertib in Uveal Melanoma (UM)Topline results, including progression free survival (PFS) data,
More news about: IDEAYA Biosciences, Inc.
Feb 16, 2026, 08:30 ET Shallow High-Grade Cu-Au Results Continue at La Verde
open pit mine schedule, significantly reducing payback and positively impacting key financial metrics of Hot Chili's March 2025 Pre-Feasibility Study ("PFS"). Latest results include:DKD036 recorded 150 m grading 0.52% CuEq1 (0.37% Cu, 0.21 g/t Au) from 30 m depth
More news about: Hot Chili Limited
Feb 16, 2026, 06:45 ET Lilly's Retevmo (selpercatinib) delivers substantial event-free survival benefit as an adjuvant therapy in early-stage RET fusion-positive lung cancer
disease recurrence in the central nervous system (CNS) as assessed by investigator and BICR, progression-free survival on the next line of treatment (PFS2), positive predictive value (PPV) of RET tests from investigator-identified laboratories with respect to the Lilly-designated RET test,
More news about: Eli Lilly and Company
Feb 12, 2026, 19:00 ET Innovent Dosed First Participant in Phase 3 Clinical Study of IBI354 (Novel HER2 ADC) for First Line Treatment of HER2-positive Breast Cancer
pertuzumab, compared with the current standard-of-care, paclitaxel plus trastuzumab and pertuzumab (THP). The primary endpoint is progression-free survival (PFS).Previously, in a multicenter Phase 1/2 study in participants with advanced solid tumors, a total of 88 participants with HER2-positive breast
More news about: Innovent Biologics
Feb 11, 2026, 09:42 ET Polymetallic Explorers Gain Ground as Copper Deficit Reshapes Discovery Premiums
Studies. Assay results for 91 holes were prepared in mid-January for inclusion into the NI 43-101 Mineral Resource Estimate that will be used in the PFS, representing a substantial increase over the 39 holes considered in the 2025 El Cura maiden MRE.Amaroq (TSXV: AMRQ) (OTCQX: AMRQF) has
More news about: Equity Insider
Feb 11, 2026, 07:00 ET Mayfair Gold Presents the Initial Results from the 2025 Grade Control Drilling Program at the Fenn-Gib Project
confidence in the highest‑grade, early years of the Fenn‑Gib mine. While preliminary, they indicate potential for positive grade reconciliation, support the PFS early‑year assumptions, and are providing important data to advance project financing. Remaining assays are expected in Q1 2026."The Grade
More news about: Mayfair Gold Corp.
Feb 10, 2026, 17:31 ET PROTAC Market Shows Accelerated Growth During the Forecast Period (2025-2034) Amid Rising Targeted Therapy Demand | DelveInsight
the Phase III VERITAC-2 trial, which met its primary endpoint in the ESR1m population, showing a significant improvement in progression-free survival (PFS) compared to fulvestrant, exceeding the pre-specified target Hazard Ratio (HR) of 0.60. However, the trial did not reach statistical significance in
More news about: DelveInsight Business Research LLP
Feb 10, 2026, 09:17 ET What Americans Really Want in 2026: A Car for Gen Z, a Vacation for Millennials, Retirement Security for Gen X
on debt reduction. "Our survey findings highlight just how differently each generation is experiencing today's economy," says Pamela Ladd, CPA/PFS AICPA's Senior Manager of Personal Financial Planning. "While Gen Z's goals for 2026 are focused on major life milestones like buying a car or home,
More news about: AICPA
Feb 10, 2026, 07:01 ET 1911 Gold Delivers Positive PEA for True North Highlighting Robust Economics with Low Capital Intensity and High Returns
plan, in preparation for inclusion in the planned Pre-Feasibility Study ("PFS") mine planDrill test extensions of planned mining areas within the first years of the PEA to add additional resources for inclusion in the PFSRegain access and re-establish infrastructure to all of the
More news about: 1911 Gold Corporation
Feb 09, 2026, 09:07 ET New Study in JNCCN Unlocks Important Information About How to Treat Recurring Prostate Cancer
showed no visible disease on the scans (T0N0M0) had the most favorable PFS, and whole-pelvis radiotherapy (WPRT) had no significant benefit compared to prostate bed radiotherapy alone. However, WPRT did significantly improve PFS for patients with local, visible disease (TrN0M0). For patients with nodal
More news about: National Comprehensive Cancer Network